The atlas functions as a centralized intelligence layer for the company’s preclinical operations, organizing vast amounts of historical data including pharmacodynamics, pathology, and immune endpoints. By automating field extraction and terminology mapping, the system assists researchers in navigating the variability inherent in autoimmune and allergic disease models. The tool is designed to support critical study decisions, such as N-size planning and endpoint selection, while maintaining strict data boundaries to protect client confidentiality.

To ensure integrity, the platform explicitly excludes raw data from client projects and any information that could compromise proprietary drug pipelines. Instead, the focus remains on leveraging historical response patterns and standardized validation metrics. According to the Head of Translational Medicine at HKeyBio, the long-term value lies in the ability to interpret pathology and biomarker experience through a more structured, AI-enhanced lens. The company intends to distill these insights into white papers and selection guides, providing a clearer roadmap for navigating the complexities of translational research.